Exact Sciences (STU:EXK) EV-to-EBIT : -56.47 (As of May. 23, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Exact Sciences's Enterprise Value is €10,847 Mil. Exact Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-192 Mil. Therefore, Exact Sciences's EV-to-EBIT for today is -56.47.

The historical rank and industry rank for Exact Sciences's EV-to-EBIT or its related term are showing as below:

STU:EXK' s EV-to-EBIT Range Over the Past 10 Years
Min: -84.59 Med: -22.03 Max: -1.58
Current: -56.38

During the past 13 years, the highest EV-to-EBIT of Exact Sciences was -1.58. The lowest was -84.59. And the median was -22.03.

STU:EXK's EV-to-EBIT is ranked worse than
100% of 103 companies
in the Medical Diagnostics & Research industry
Industry Median: 22.43 vs STU:EXK: -56.38

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Exact Sciences's Enterprise Value for the quarter that ended in Mar. 2024 was €13,059 Mil. Exact Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-192 Mil. Exact Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1.47%.

Exact Sciences EV-to-EBIT Historical Data

The historical data trend for Exact Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences EV-to-EBIT Chart

Exact Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-35.92

-26.45

-17.92

-17.17

-85.69

Exact Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-27.33	-44.27	-52.93	-85.69	-69.91

Competitive Comparison of Exact Sciences's EV-to-EBIT

For the Diagnostics & Research subindustry, Exact Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Sciences's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Exact Sciences's EV-to-EBIT falls into.

Exact Sciences EV-to-EBIT Calculation

Exact Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	10846.684	/	-192.084
	=	-56.47

Exact Sciences's current Enterprise Value is €10,847 Mil.
Exact Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-192 Mil.

Exact Sciences (STU:EXK) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Exact Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-192.084	/	13059.20495
	=	-1.47 %

Exact Sciences's Enterprise Value for the quarter that ended in Mar. 2024 was €13,059 Mil.
Exact Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-192 Mil.

Exact Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Exact Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Sciences (STU:EXK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

EXAS:USA

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.